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VALIDITY AND RELIABILITY OF AN AMERICAN
TRANSLATION OF THE ST. GEORGE'S
RESPIRATORY QUESTIONNAIRE
Barr JT, Schumacher GE, Freeman S, Collette K,
PROAS Group
PROAS Group, Northeastern University and Massachusetts
Association of Cardiovascular and Pulmonary Rehabilitation,
Boston, MA, USA
A self-administered, disease-specific form of health status
instrument for patients with COPD is not available in
America. The St. George's Respiratory Questionnaire
(SGRQ) is a successful measure in Great Britain and Eu-
rope that meets these requirements, but syntax and collo-
quial differences make an American version necessary.
OBJECTIVE: To test the validity and reliability of an
American translation (ATSGRQ) of the SGRQ.
METHODS: Two bilingual health professionals indepen-
dently translated the SGRQ based on summarized input
from panels of American COPD patients and American
respiratory professionals. Consensus was reached on the
translated version and then back-translated by two other
bilingual health professionals. To establish reliability, the
ATSGRQ was given to COPD patients at the beginning
of a pulmonary rehabilitation program (PRP) and re-
peated 1 week later. To establish validity, the ATSGRQ
was used with pulmonary function tests, the Medical Re-
search Council's dyspnea scale (DYS), 6-minute walk
(6MW), and Short Form Health Status Profile-36 (SF-36)
at the beginning and end of PRP for 24 COPD patients.
RESULTS: The patients were mean age 70 yr, 40% male,
mean FEV1 = 0.95. The ATSGRQ Cronbach's alpha for
overall scale and symptom, activity, and impact compo-
nents was respectively .87, .65, .79, .80. Test-retest cor-
relations were .70, .60, .72, .64, respectively. Baseline
correlations between total ATSGRQ and FEV1, DYS,
6MW, and SF-36 physical and mental health component
scores were -.43, .54, .56, -.76, -.62. From initial to
post-PRP, the symptom ATSGRQ decreased 12.6% (p =
.004); DYS decreased 10.6% (p = .043).
CONCLUSION: Based on these preliminary data, the
ATSGRQ appears to be a valid, reliable health status in-
strument for use in an American COPD population.
PCDI2
COST OF PRESCRIPTION DRUGS AND COST OF
TREATMENT FAILURE FOR SINUSITIS
Nadesan B, Cady PS, Force RW, Force WS, Culbertson VL
Department of Pharmacy Practice and Administrative Sciences,
Idaho State University, Pocatello, ID, USA
This study shows the cost of drug treatment failure, illus-
trating the need for initial treatment success with proper
drug choice and compliance.
OBJECTIVE: This study examines the cost of prescrip-
tion drugs used in the treatment of sinusitis and the cost
of treatment failure. Economic costs are strong incentives
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to treat a disease effectively, reducing relapses and antibi-
otic resistance.
METHODS: The Idaho Medicaid database was used to
analyze drug costs. The data was divided into 2 groups, a
less than 15 but more than 1 year old group labeled
Group 1. Group 2 consisted of patients 15 or more than
15 years old. The treatment was considered a failure
when a patient returned within 30 days of a physician
visit. Thus all treatment failures could be captured.
RESULTS: There were 15,568 patients (9.8%) who had
at least one diagnosis of sinusitis, comprising 36.2%
males and 63.8% females. The total cost of prescription
drugs was $529,065. For Group 1, the total cost of drugs
for the first episode was $182,499 written for 6,594 pa-
tients. Of these, 450 patients had a treatment failure,
costing $17,365, of which Amoxicillin TriPot. Clav. ac-
counted for 31 % of drug cost. For Group 2, the total cost
of drugs for the first episode was $264,030 written for
7,107 patients. Of these, 592 patients had a treatment
failure, costing $37,183. Amoxicillin Tr/Pot. Clav. ac-
counted for 22.3% of drug cost for treatment failure.
CONCLUSION: The results show that more expensive
drugs are used for treatment failure. This is an incentive
for ensuring that a treatment succeeds with proper selec-
tion and compliance of drug therapy.
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DOES THE DURATION OF PULMONARY
REHABILITATION AFFECT THE
MAGNITUDE OF PATIENT RESPONSE?
Barr JT, Schumacher GE, Coleman AM, PROAS Group
PROAS Group, Northeastern University and Massachusetts
Association of Cardiovascular and Pulmonary Rehabilitation,
Boston, MA, USA
OBJECTIVE: To determine if there is a dosage effect asso-
ciated with the length of pulmonary rehabilitation (PR).
METHODS: We used a battery of outcome measures to
quantify the amount of change that was achieved from
baseline to discharge in 286 patients completing a PR
program in 1 of 12 institutions participating in PROAS.
The programs were of varying durations. Paired t-tests
indicated overall that while the pulmonary rehabilitation
programs did not yield improvements in physiologic
(FEV1, FVC, % predicted FEV1) outcomes, the patients
did achieve significant improvements in symptomatic
(Borg score), functional (6-minute walk), general health-
related quality of life [SF-36 Health Survey (SF-36)], and
disease-specific HRQL [Chronic Respiratory Disease
Questionnaire (CRQ)] variables.
RESULTS: Based on a series of stepwise multiple regres-
sions using the amount of change in each outcome variable
as the dependent variable and adjusting for the corre-
sponding baseline value and 11 clinical and sociodemo-
graphic characteristics, the number of hours of education
(HREDU, 13.5 hr ± 6.7), activities of daily living
(HRADL, 2.2 hr ± 6.6), and psychosocial support (6.5 hr ±
5.6) both individually and collectively (42.4 hr ± 11.8)
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generally did not contribute to explaining the magnitude
of change achieved by the patients. However, the number
of hours of supervised exercise (HREX, 25.4 hr ± 9.2)
did contribute to explaining increases in 5 of the 8 SF-36
domains: physical function (p = 0.027), physical role
(p = 0.0002), health perceptions (p = 0.0167), vitality
(p = 0.034), and social function (p = 0.0035).
CONCLUSION: These data suggest that outcomes spe-
cifically related to pulmonary diseases are not affected by
a longer duration for this type of intervention, but that
broader, population-based assessments may need an ad-
ditional period of intervention, or elapsed time, to detect
improvement.
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A HEALTH ECONOMIC ANALYSIS OF
FLUTICASONE PROPIONATE, BUDESONIDE,
AND BECLOMETHASONE DIPROPIONATE
FOR THE TREATMENT OF MODERATE
TO SEVERE ASTHMA.
Trakas K', Oh PII,2, Einarson TR', Shear NHI,2
IUniversity of Toronto, Toronto, Canada;2Sunnybrook Health
Science Centre, Toronto, Canada
OBJECTIVES: To determine the relative cost-effective-
ness of the inhaled corticosteroids beclomethasone dipro-
pion ate (BDP), budesonide (BUD), and fluticasone propi-
onate (FP), for managing moderate to severe asthma in
adults over a one-year time horizon from the perspective
of the Ministry of Health (MOH) in Canada.
METHODS: A single-arm meta-analysis of randomized
control trials containing at least one of FP, BUD, and BDP
was performed in order to derive estimates of effectiveness
and tolerance. A decision tree analysis was then used to
model the cost-effectiveness analysis. Only direct medical
costs were included in the analysis (i.e., inpatient care,
emergency visits, physician services, nursing services,
drugs, diagnostic tests). The time horizon of the study was
52 weeks, precluding discounting. All costs are presented
in 1996 Canadian dollars (CDN$). The cost-effectiveness
was the cost per additional symptom-free day ($/SFD).
RESULTS: 69 of 398 articles were included in the meta-
analysis. The Monte Carlo base case analysis showed that
FP and BUD resulted in an annual cost of $1,383 and
$1,147 respectively (p < 0.01). FP produced 216 SFDs
while BUD resulted in 214 SFDs, which were not signifi-
cantly different at p = 0.01 (corrected for multiple com-
parisons). BDP cost $1,343/year and yielded 213 SFD/
year (BDP was excluded from the final analysis, domi-
nated by BUD). With no difference in effectiveness, a
cost-minimization analysis showed that BUD was the
cost-effective alternative, costing $236 CDN less than the
FP strategy.
CONCLUSIONS: Of the inhaled corticosteroids avail-
able on the MOH Formulary in Canada, BUD is a cost-
effective alternative for the treatment of adults with mod-
erate to severe asthma.
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VETERANS' SATISFACTION WITH
H2-RECEPTOR ANTAGONIST
(H2RA) DRUG CONVERSION
Department of Veterans Affairs Medical Center, San Francisco,
CAUSA
The Veterans Health Administration awarded national pur-
chasing contracts for the H2RAs to cimetidine and famoti-
dine. Our patients were taking ranitidine but were switched
to one of the two contracted agents. The conversion process
was performed by a pharmacist via local protocol. Patients
were contacted by phone and mailed a handout explaining
the rationale for the medication switch.
OBJECTIVES: To evaluate how patients feel concerning
their new H2RA and the way we informed them of the
conversion.
METHODS: In this cross-sectional study, a "generic drug
conversion" patient satisfaction questionnaire was mailed
to 295 patients converted to either cimetidine (53 pa-
tients) or famotidine (242 patients).
RESULTS: There were 181 returned questionnaires, a
61.3% total response rate. Patient responses were as fol-
lows: 69.4% answered that their new H2RA works the
same or better than ranitidine; 16.4% answered that their
new H2RA had more side effects/problems than raniti-
dine; 80.4% answered that the conversion process was
clearly explained to them; 13.3% of patients contacted
the VA concerning their new H2RA medication; 76.4%
answered that the way they were informed of the conver-
sion was good to excellent. The only difference found, af-
ter subgroup analysis, was that 48.2 % of the cimetidine
patients subjectively rated it to work worse than raniti-
dine, versus 27.1 % of the famotidine patients, using their
own criteria (Chi-square, p < 0.028; OR 2.51).
CONCLUSIONS: The data suggest that the majority of the
patients believe their new H2RA works well for them and
are satisfied with the conversion process. Of the patients
who rated their new H2RA to work worse than ranitidine,
there is a 2.51 times greater chance that they were taking ci-
metidine as compared to patients whose H2RA worked
worse than ranitidine and were taking famotidine.
